A Phase 3 interventional study of Tobramycin Powder and Colistin in Cystic Fibrosis With Pulmonary Manifestations, sponsored by University Hospital Tuebingen. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-11-14.
Sponsored by University Hospital Tuebingen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess whether the inhalative combination of Tobramycin/Colistin is more effective in reducing Pseudomonas colony forming units (CFUs) and improvement of lung function than Colistin in mono-therapy.
Cystic fibrosis (CF), the most common autosomal recessive disorder in Western countries, is caused by mutations of the cystic fibrosis transmembrane conductance regulator molecule (CFTR) and affects approximately 40.000 patients in Europe. The majority of CF patients develop chronic pulmonary infections with Pseudomonas aeruginosa. These are normally treated with single antibiotics, administered orally, intravenously or inhalatively. Once the infection becomes chronic, eradication of the pathogen is not any more possible due to biofilm formation of the pathogen and increasing resistance. However, inhalative antibiotic combination therapy might be more efficient than single antibiotic therapy in chronically infected CF patients. This notion is supported by previous in vitro and animal studies using Tobramycin/Colistin combination therapy. Importantly, a pilot study in five CF patients who inhaled consecutively Colistin and Tobramycin solutions for 4 week, revealed a decrease of log10 2.52 ± 2.5 cfu of P. aeruginosa in sputum specimens during the course of the treatment compared to baseline values (p=0.027). The treatment was shown to be safe and well tolerated. However, forced expiratory volume in 1 sec (FEV1) did not differ significantly.
Taking advantage of the new development of dry powder inhalation (DPI) antibiotics, specifically TOBI© Podhaler, a larger randomised trial has been performed in which the combined TOBI© Podhaler and Colistin treatment is compared to the monotherapy with Colistin.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
This study's enrollment of 26 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Browse Cystic Fibrosis studies →University Hospital Tuebingen is the lead sponsor of 491 studies on the registry; 109 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off); and Colistin solution 2 x daily 1 Mega continuously for 112 days
Drug: Tobramycin Powder · Drug: Colistin
Colistin solution 2 x daily 1 Mega continuously for at least 30 days
Drug: Colistin
TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);
Also known as: TOBI®Podhaler
Colistin solution 2 x daily 1 Mega continuously
Also known as: Colistin solution
Amount of P. aeruginosa in sputum
The primary endpoint will be the difference of P. aeruginosa cfu/ml in sputum with combined therapy with Tobramycin/Colistin compared to colistin mono-therapy. The analysis will be adjusted for baseline values of each cycle and parametric (paired t-Test) or non-parametric (sign test) methods will be used as appropriate.
Time frame: 30 days
Course of P.aeruginosa amount in sputum
Course of P. aeruginosa in sputum measured as cfu/ml during the study
Time frame: 112 days
Course of forced vital capacity (FVC) absolute amount
Course of FVC absolute in litres during the study
Time frame: 112 days
Course of FVC relative amount
Course of FVC relative (percent of expected amount for given body height and gender) during the study
Time frame: 112 days
Course of FEV1 absolute amount
Course of FEV1 absolute in litres during the study
Time frame: 112 days
Course of FEV1 relative amount
Course of FEV1 relative (percent of expected amount for given body height and gender) during the study
Time frame: 112 days
Course of MEF25-75 absolute amount
Course of MEF25-75 absolute in litres during the study
Time frame: 112 days
Course of MEF25-75 relative amount
Course of MEF25-75 relative (percent of expected amount for given body height and gender) during the study
Time frame: 112 days
Course of proinflammatory cytokine IL1ß amount
Course of proinflammatory cytokine IL1ß amount in sputum \[pg/ml\] during the study
Time frame: 112 days
Course of proinflammatory cytokine IL6 amount
Course of proinflammatory cytokine IL6 amount in sputum \[pg/ml\] during the study
Time frame: 112 days
Course of proinflammatory cytokine IL8 amount
Course of proinflammatory cytokine IL8 amount in sputum \[pg/ml\] during the study
Time frame: 112 days
Course of antiinflammatory cytokine IL10 amount
Course of antiinflammatory cytokine IL10 amount in sputum \[pg/ml\] during the study
Time frame: 112 days
Course of proinflammatory cytokine TNFa amount
Course of proinflammatory cytokine TNFa amount in sputum \[pg/ml\] during the study
Time frame: 112 days
Course of proinflammatory cytokine GM-CSF amount
Course of proinflammatory cytokine GM-CSF amount in sputum \[pg/ml\] during the study
Time frame: 112 days
Course of DNA amount in sputum
Course of DNA amount {pg/ml\] in sputum during the study
Time frame: 112 days
Course of leukocyte amount in sputum
Course of leukocyte amount \[pg/ml\] in sputum during the study
Time frame: 112 days
Exacerbation
Number of exacerbations during the study
Time frame: 112 days
Antibiotics
Use of antibiotics during the study
Time frame: 112 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2014 to primary completion in Dec 2015, 21 months.
Of 67 phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 39. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Tuebingen →